DeCure for Pyogenic arthritis-pyoderma gangrenosum-acne syndrome
DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for pyogenic arthritis-pyoderma gangrenosum-acne syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePyogenic arthritis-pyoderma gangrenosum-acne syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pyogenic arthritis-pyoderma gangrenosum-acne syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1) — PSTPIP1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7AAL · 1.97 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
In a 2009 report, one patient with PAPA syndrome (pyogenic arthritis, pyoderma gangrenosum and acne) showed rapid and lasting healing of pyoderma gangrenosum after treatment with the recombinant human interleukin-1 receptor antagonist anakinra. The abstract gives no sample size beyond that single case, no numeric outcomes such as time to healing or duration of response, and no comparison group.
A 1995 case describes a 16-year-old male whose pyoderma gangrenosum appeared together with acne conglobata and a seronegative spondyloarthropathy. Treatment with isotretinoin was successful: both acne and pyoderma lesions healed and articular symptoms improved. Again, this is a single patient, with no controlled data.
A 2022 review of PASH syndrome (pyoderma gangrenosum, acne, and hidradenitis suppurativa, without arthritis) reports one patient who did not respond to immunosuppressive treatment but did respond to a combination of colchicine and thalidomide. The review notes that PASH syndrome is distinguished from PAPA, PA-PASH, and PASS syndromes by the absence of pyogenic sterile arthritis. The abstract states that the exact cause of PASH remains unknown and that both PG and hidradenitis suppurativa are considered autoinflammatory, with neutrophil-rich infiltration and overexpression of interleukin-1 family members.
A 2015 report describes a boy with PAPA syndrome whose treatment with an interleukin-1 receptor antagonist (anakinra) revealed an active hepatitis B infection. The abstract does not provide numeric data on joint or skin outcomes for this patient; its main point is the complication of infection unmasked by the biologic therapy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Dermatology · 2009 · 222 citations
Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra
AbstractThe triad of sterile pyogenic arthritis, pyoderma gangrenosum and acne is known by the acronym of PAPA syndrome. It is a rare autosomal dominant disease of early onset. The treatment of pyoderma gangrenosum is challenging as there is often only partial response to systemic glucocorticosteroids and immunosuppressive therapies. We report the rapid and lasting response of pyoderma gangrenosum to the targeted treatment with the recombinant human interleukin-1 receptor antagonist (rHuIL-1Ra) anakinra in a patient with PAPA syndrome.
Clinical and Experimental Dermatology · 1995 · 21 citations
Pyoderma gangrenosum associated with acne conglobata
AbstractWe report a 16-year-old male in whom pyoderma gangrenosum appeared in conjunction with acne conglobata. The patient also developed a seronegative spondyloarthropathy that was the main presenting complaint. There was no evidence of inflammatory bowel disease. Treatment with isotretinoin was successful. Both acne and pyoderma lesions healed and the articular symptoms improved. The present case, together with other reports in the literature show that acne conglobata must be included in the list of possible associations of pyoderma gangrenosum. We also comment on acne arthritis, a relatively frequent phenomenon, although still not generally known, in acne conglobata.
Frontiers in Medicine · 2022 · 17 citations · open access
Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome: A Case Report and Literature Review
AbstractPyoderma gangrenosum, acne, and hidradenitis suppurativa syndrome is a rare inflammatory disease characterized by pyoderma gangrenosum (PG), mild to severe facial acne, and hidradenitis suppurativa (HS). It only affects the skin and represents cutaneous characteristics of a spectrum of autoinflammation. Lack of pyogenic sterile arthritis (PA) distinguishes the pyoderma gangrenosum, acne, and hidradenitis suppurativa (PASH) syndrome from pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PA-PASH), pyoderma gangrenosum, acne, hidradenitis suppurtiva, and ankylosing spondylitis (PASS), and pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndromes. The exact etiology and pathogenesis of PASH syndrome remain unknown. Both PG and HS are contained in the spectrum of neutrophilic dermatitis, which is considered as an autoinflammatory syndrome. From a pathophysiological point of view, they show similar mechanisms, including neutrophil-rich cutaneous infiltration and overexpression of the interleukin-1 (IL-1) family. These findings provide guidance for these intractable diseases. In this review, we described a case of PASH syndrome in a patient who initially failed to respond to immunosuppressive treatment but responded to a combination of colchicine and thalidomide. We reviewed the relevant literature that focuses on PASH syndrome management.
Pediatric Rheumatology · 2015 · 2 citations · open access
Interleukin-1 receptor antagonist treatment revealed active hepatitis B infection in a boy with PAPA syndrome
AbstractPAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum and acne) is a rare autosomal-dominant autoinflammatory disease caused by mutations in PSTPIP1gene. Typically presents with recurrent sterile, erosive arthritis in childhood, occurring spontaneously or after minor trauma, occasionally resulting in significant joint destruction. By puberty, joint symptoms tend to subside and cutaneous symptoms increase. Cutaneous manifestations include pathergy, frequently with abscesses at the sites of injections, severe cystic acne, and recurrent nonhealing sterile ulcers, often diagnosed as PG. To report a case of hepatitis B infection revealed with interleukin-1 receptor antagonist for PAPA syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
